Small cell lung cancer: Clinical Practice Guidelines in Oncology™

Bruce E. Johnson; Jeffrey Crawford; Robert J. Downey; David S. Ettinger; Frank Fossella; John C. Grecula; Thierry Jahan; Gregory P. Kalemkerian; Anne Kessinger; Marianna Koczywas; Corey J. Langer; Renato Martins; Maryanne Hoffman Marymont; Harvey B. Niell; Nithya Ramnath; Francisco Robert; Charles C. Williams

doi:10.6004/jnccn.2006.0050

Small cell lung cancer: Clinical Practice Guidelines in Oncology™

Bruce E. Johnson, Jeffrey Crawford, Robert J. Downey, David S. Ettinger, Frank Fossella, John C. Grecula, Thierry Jahan, Gregory P. Kalemkerian, Anne Kessinger, Marianna Koczywas, Corey J. Langer, Renato Martins, Maryanne Hoffman Marymont, Harvey B. Niell, Nithya Ramnath, Francisco Robert, Charles C. Williams

Oncology/Hematology

Research output: Contribution to journal › Review article › peer-review

42 Scopus citations

Abstract

In 2005, approximately 26,000 new cases of small cell lung cancer were diagnosed in the United States. When compared with non-small cell lung cancer, SCLC generally has a more rapid doubling time, a higher growth fraction, and earlier development of widespread metastases. SCLC is highly sensitive to initial chemotherapy and radiotherapy. Treatment with chemotherapy plus chest radiotherapy can be curative for some patients with limited-stage SCLC, whereas most patients with extensive-stage disease who undergo chemotherapy alone experience palliated symptoms and prolonged survival. The updated 2006 NCCN guidelines include new principles of surgical resection as well as chemotherapy and radiation dosage changes.

Original language	English (US)
Pages (from-to)	602-622
Number of pages	21
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	4
Issue number	6
DOIs	https://doi.org/10.6004/jnccn.2006.0050
State	Published - Jul 2006

Keywords

Carcinoma
Chemotherapy
Mediastinum
Metastases
NCCN Clinical Practice Guidelines
Pulmonary carcinogenesis
Radiotherapy
Small cell
Surgical resection
Targeted therapy

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2006.0050

Cite this

Johnson, B. E., Crawford, J., Downey, R. J., Ettinger, D. S., Fossella, F., Grecula, J. C., Jahan, T., Kalemkerian, G. P., Kessinger, A., Koczywas, M., Langer, C. J., Martins, R., Marymont, M. H., Niell, H. B., Ramnath, N., Robert, F., & Williams, C. C. (2006). Small cell lung cancer: Clinical Practice Guidelines in Oncology™. JNCCN Journal of the National Comprehensive Cancer Network, 4(6), 602-622. https://doi.org/10.6004/jnccn.2006.0050

Johnson, BE, Crawford, J, Downey, RJ, Ettinger, DS, Fossella, F, Grecula, JC, Jahan, T, Kalemkerian, GP, Kessinger, A, Koczywas, M, Langer, CJ, Martins, R, Marymont, MH, Niell, HB, Ramnath, N, Robert, F & Williams, CC 2006, 'Small cell lung cancer: Clinical Practice Guidelines in Oncology™', JNCCN Journal of the National Comprehensive Cancer Network, vol. 4, no. 6, pp. 602-622. https://doi.org/10.6004/jnccn.2006.0050

@article{510da461043a4f90a181949422456c6f,

title = "Small cell lung cancer: Clinical Practice Guidelines in Oncology{\texttrademark}",

abstract = "In 2005, approximately 26,000 new cases of small cell lung cancer were diagnosed in the United States. When compared with non-small cell lung cancer, SCLC generally has a more rapid doubling time, a higher growth fraction, and earlier development of widespread metastases. SCLC is highly sensitive to initial chemotherapy and radiotherapy. Treatment with chemotherapy plus chest radiotherapy can be curative for some patients with limited-stage SCLC, whereas most patients with extensive-stage disease who undergo chemotherapy alone experience palliated symptoms and prolonged survival. The updated 2006 NCCN guidelines include new principles of surgical resection as well as chemotherapy and radiation dosage changes.",

keywords = "Carcinoma, Chemotherapy, Mediastinum, Metastases, NCCN Clinical Practice Guidelines, Pulmonary carcinogenesis, Radiotherapy, Small cell, Surgical resection, Targeted therapy",

author = "Johnson, {Bruce E.} and Jeffrey Crawford and Downey, {Robert J.} and Ettinger, {David S.} and Frank Fossella and Grecula, {John C.} and Thierry Jahan and Kalemkerian, {Gregory P.} and Anne Kessinger and Marianna Koczywas and Langer, {Corey J.} and Renato Martins and Marymont, {Maryanne Hoffman} and Niell, {Harvey B.} and Nithya Ramnath and Francisco Robert and Williams, {Charles C.}",

year = "2006",

month = jul,

doi = "10.6004/jnccn.2006.0050",

language = "English (US)",

volume = "4",

pages = "602--622",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "6",

}

TY - JOUR

T1 - Small cell lung cancer

T2 - Clinical Practice Guidelines in Oncology™

AU - Johnson, Bruce E.

AU - Crawford, Jeffrey

AU - Downey, Robert J.

AU - Ettinger, David S.

AU - Fossella, Frank

AU - Grecula, John C.

AU - Jahan, Thierry

AU - Kalemkerian, Gregory P.

AU - Kessinger, Anne

AU - Koczywas, Marianna

AU - Langer, Corey J.

AU - Martins, Renato

AU - Marymont, Maryanne Hoffman

AU - Niell, Harvey B.

AU - Ramnath, Nithya

AU - Robert, Francisco

AU - Williams, Charles C.

PY - 2006/7

Y1 - 2006/7

N2 - In 2005, approximately 26,000 new cases of small cell lung cancer were diagnosed in the United States. When compared with non-small cell lung cancer, SCLC generally has a more rapid doubling time, a higher growth fraction, and earlier development of widespread metastases. SCLC is highly sensitive to initial chemotherapy and radiotherapy. Treatment with chemotherapy plus chest radiotherapy can be curative for some patients with limited-stage SCLC, whereas most patients with extensive-stage disease who undergo chemotherapy alone experience palliated symptoms and prolonged survival. The updated 2006 NCCN guidelines include new principles of surgical resection as well as chemotherapy and radiation dosage changes.

AB - In 2005, approximately 26,000 new cases of small cell lung cancer were diagnosed in the United States. When compared with non-small cell lung cancer, SCLC generally has a more rapid doubling time, a higher growth fraction, and earlier development of widespread metastases. SCLC is highly sensitive to initial chemotherapy and radiotherapy. Treatment with chemotherapy plus chest radiotherapy can be curative for some patients with limited-stage SCLC, whereas most patients with extensive-stage disease who undergo chemotherapy alone experience palliated symptoms and prolonged survival. The updated 2006 NCCN guidelines include new principles of surgical resection as well as chemotherapy and radiation dosage changes.

KW - Carcinoma

KW - Chemotherapy

KW - Mediastinum

KW - Metastases

KW - NCCN Clinical Practice Guidelines

KW - Pulmonary carcinogenesis

KW - Radiotherapy

KW - Small cell

KW - Surgical resection

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=33747592358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747592358&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2006.0050

DO - 10.6004/jnccn.2006.0050

M3 - Review article

C2 - 16813728

AN - SCOPUS:33747592358

SN - 1540-1405

VL - 4

SP - 602

EP - 622

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 6

ER -

Small cell lung cancer: Clinical Practice Guidelines in Oncology™

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this